Christopher Liu
Stock Analyst at Leerink Partners
(2.98)
# 1,554
Out of 5,042 analysts
9
Total ratings
83.33%
Success rate
37.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $38.72 | +23.97% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $17.64 | +13.38% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $1.79 | +402.77% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $7.82 | +27.88% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $6.86 | +162.39% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $29.18 | -7.47% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $93.39 | -55.03% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $38.72
Upside: +23.97%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $17.64
Upside: +13.38%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $1.79
Upside: +402.77%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $7.82
Upside: +27.88%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $6.86
Upside: +162.39%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $29.18
Upside: -7.47%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $93.39
Upside: -55.03%